What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis-Reference-Cited by-同舟云学术

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

Published:2018-06-13 Issue:2 Volume:8 Page:247-258
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Athauda Dilan¹,Maclagan Kate²,Budnik Natalia³,Zampedri Luca³,Hibbert Steve²,Skene Simon S.²⁴,Chowdhury Kashfia²,Aviles-Olmos Iciar¹,Limousin Patricia¹,Foltynie Thomas¹

Affiliation:

1. Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

2. UCL Comprehensive Clinical Trials Unit (UCL CCTU)

3. Leonard Wolfson Experimental Neuroscience Centre, London, UK

4. University of Surrey, Surrey Clinical Trials Unit, UK

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference26 articles.

1. Non-motor symptoms of Parkinson’s disease: Diagnosis and management;Chaudhuri;Lancet Neurol,2006

2. Sydney multicenter study of Parkinson’s disease: Non-L-dopa-responsive problems dominate at 15 years;Hely;Mov Disord,2005

3. Sex differences in clinical features of early, treated Parkinson’s disease;Augustine;PLoS One,2015

4. Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1;Parkes;Expert Opin Drug Discov,2013

5. Exenatide once weekly versus placebo in Parkinson’s disease: A randomised, double-blind, placebo-controlled trial;Athauda;Lancet,2017

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease;European Journal of Pharmacology;2024-11

2. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27

3. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?;Neuropharmacology;2024-08

4. Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson’s Disease Patients;CNS & Neurological Disorders - Drug Targets;2024-05

5. The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology;International Journal of Molecular Sciences;2024-04-15